Skip to main content
Quest Diagnostics

Prediction of Severe COVID-19 Based on Routine Biomarker Assessment

Annual Scientific Meeting & Clinical Lab Expo

AACC 2023

Anaheim, CA, July 23-27 , 2023

Poster presentation: Prediction of Severe COVID-19 Based on Routine Biomarker Assessment

Authors: Kapoor H, Bi C, Salm AE, Szymanski J, Goldstein Y, Wolgast LR, Rosenblatt G, Fox A, Kroll MH

Specialty: Infectious Disease, COVID-19

Related content

Conference Presentation
Coinfection Rates of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Conference Presentation
SARS-CoV-2 IGM Detection in Relation To Reactivity In 4 SARS-Cov-2 IGG Assays
Test FAQ
SARS CoV 2 Antibody Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.